Before we formally start, the usual safe harbor statement and disclaimer. Basically, the performance and results of operation contained in this presentation are historical in nature, and past performance is no guarantee of future results. Let's start. You know, we have this summary slide that I think quite succinctly covers our past, our current, and most importantly, our future direction. On the left-hand side of this slide, you have the circle saying "Global Commercial Success," and we are very happy to have our innovative drug-free sector doing very well during the first half of this year with sales up 25%. Again, for those who know this, you know, we have been selling in China for a couple of years, but, you know, we got FDA approval in 2023. Our marketing partner, Takeda, has been doing a fantastic job ramping it up in the US, in Europe, and Japan over the last little bit more than a year, and, you know, it has been doing great. Of course, this not just validates our science, but it also provides us with a very strong financial foundation, helping us to be profitable since 2023, 2024, and we expect to remain self-sufficient in our capital funding in the upcoming years thanks to this innovative drug finally materializing in global sales. We are expecting the second one. This is a drug called ORPATHYS for lung cancer. You know, it has been going through both China trials and global trials. The trial name is called Saffron. We anticipate completion very soon, and then the readout of the data will be the first half of next year. Our marketing partner, AstraZeneca, you know, when this product potentially gets approved in the US, will be commercializing this one. We hope that will be sometime around 2027. You know, I think with these two products, we hopefully will have two commercial global products supporting both our financial as well as validating our science. I probably won't go over into too much details of the near-term catalysts. Oh, by the way, this presentation is also on our homepage, so if you miss anything, you can definitely go back to download this presentation on the HUTCHMED homepage. We do have a couple of upcoming catalysts in the next 12 months, definitely very relevant for our stock price performance. I definitely want to spend more time today to talk about our future, which we have in new generation technology platform called ATTC, Antibody Targeted Therapy Conjugate. I think many of you have already heard of the term called ADC, ADC, right? I think you can look at our ATTC to be the next generation of ADC and even more improved version of ADC, focusing specifically on improving the safety and the toxicity of this kind of molecules, initially target oncology, but maybe down the road, it may also have potential autoimmune application. The very first drug candidate coming up from our ATTC platform, that one is called A251. We had just presented the preclinical data in the EORTC conference just a little bit two weeks ago in Boston. Right last Friday, we also hosted an R&D day, both online and offline, explaining even in more detail by our Chief Medical Officer on our very first molecule. For those who may have missed that, again, the webcast replay is also on our homepage for our ATTC platform. The reason why I say this is very important is not, is that because this is not just one molecule. If this ATTC platform works, it will generate many, many more drug molecules. Of course, it is still at an early stage. We had got some very good preclinical evidence, and then our plan is to get it into patient phase one trial in December this year. We had already got the IND approval in the U.S., and we are pending to receive the IND approval in China. Expect 2026 next year to be a year full of news and events coming out from this platform. Apart from the science, which we think we are global first in this so-called ATTC category, the other thing that we bring a lot of attention to this is the potential outlicensing opportunities. We have been attracting a lot of interest from global pharma into this platform, and there are possibilities of BD opportunities when we disclose more clinical data down the road. I think, you know, on this slide, we do have very solid financial foundation that makes us very self-sufficient, not relying on the capital market for further funding. At the same time, the more important thing is our ATTC platform, which if it starts to generate good results, it will provide us with an even bigger pipeline of products that we can bring to patients in need down the road. Now, we do have a very big slide deck here, so apologies for not going through every single slide, but I'll just jump to this one right here, which is our first half sales of some of our key products. Again, like HUTCHMED has been doing, quite well, up 25% first half this year. For those who have been following us even more closely, you may have looked at some of our marketing partner third quarter sales, and then, you know, we roughly have about quarter over quarter growth of around 10% for both the HUTCHMED, which is the overseas fruquintinib, and then also for domestic fruquintinib. We also start to see some quarterly over improvement. Now, you know, this is the present. Let me jump a little bit to the slide where we talk about our upcoming future potential. So first of all, our late-stage pipeline is very solid, you know, for our FRUZAQLA. We had already been selling it for colorectal cancer, but since early this year in China, we also got approval for a second indication called EMC, endometrial cancer. This is a combination therapy with another PD-1 drug that we can address the market. I think we also have the third indication called renal cell carcinoma, RCC, which we have already presented very impressive data in ESMO, the ESMO conference, just last month or early this month. We had also submitted, or filed, to the China NDA, which, if everything goes smoothly, the approval probably would land around middle next year, potentially. With that, we will actually have two more indications for Fruquintinib to support its further sales growth in China. For the other product, Savolitinib, we had got a second indication approved June 30 this year. This is the second line lung cancer focusing on the MET amplifier. MET, of course, is a biomarker, roughly in one third of the patient population in the second line EGFR setting. It's definitely a very sizable patient population. We are the only one around the world with such late-stage data focusing on the MET-specific patients. For the overseas trial, similar to this SACHI trial that you saw there, the overseas counterpart is called Saffron. I mentioned briefly just a moment ago that our marketing partner, AstraZeneca, is close to completing the recruitment and the data readout will be first half next year according to AstraZeneca guidance. If, again, everything goes smoothly, potential US approval in 2027, which may bring our second innovative drug to be globally commercialized. Back in China, we are also working on another even more impressive trial in the first line setting. This is a trial called SANOVO, fully recruited. Again, this is also a very highly contested market in the first line lung cancer space for the MET overexpression. It's a very decent market size as well, you know, ranging from 30%-50% of the first line lung cancer patients have overexpressed MET proteins. If the results are satisfactory, this will also address a very sizable market. The third drug called surufatinib, the thing to look out for is December. We will present the pancreatic phase two data at a conference, so watch out for that one. We are planning to, if the data is satisfactory, to roll it into phase three trial. Again, pancreatic cancer is what a lot of people call cold tumors, very tough-to-treat cancers. You know, we are using our Surufatinib in combination with another PD-1 and chemotherapy to target this tough-to-treat cancer. I'll skip the next one and go straight to the blue one called [serplulimab]. This one, if you remember, we presented very impressive data, durable response rate of around 51%. And this is compared to most of the new modality, just hovering around the 20%-30% durable response rate. Unfortunately, we had some CMC issues, you know, earlier this year, and we have to change to a new formulation. We do not have to redo the phase three trial, but we do have to resubmit the data. The timeline we are now anticipate, to resubmit the data for the China authorities will be first half next year. This is for the indication of ITP, which is basically your blood platelets being too low in the body, and you kind of bleed very easily. It is a chronic disease. It is an autoimmune disease. It is definitely a new area that we are very excited about, and we plan to commercialize it in China when it potentially gets approved, hopefully in 2027. It is also working on another indication, a little bit rarer disease called WARM-AIHA, second line setting. The data would be probably around early next year to present the data. If that is also successful, SOFPLA will have two potential indications, you know, addressing a very sizable market population. Now, this is, this slide and many of the slides that I just went through. For those who are familiar with HUTCHMED, you probably have seen it a couple of times before. What I am going to show you next, I think, is pretty new. The next slide we talk, we are going to talk about the early stage pipeline. Focus on the bottom three coming out from our ATTC platform. The first one is called A251, and we disclosed just two weeks ago, basically the composition of this. Now, you know, let me also jump to the next slide here, where we talk about the structure of this ATTC. It is made up of a large molecule and antibodies, right? And we disclosed that this antibody is a trastuzumab biosimilar, a HER2 targeting antibody. And it is going to have a linker, a cleavable linker. So, so far, it is still quite similar to the ADC that you have seen out there. What differentiates us from all our peers is for the payload, instead of using a non-specific chemotoxin, we are using a specific small molecule drug, right? Instead of like a chemo payload, we use a small molecule drug as the payload, which means that it will be even more selectively targeting certain mutation or certain mutated pathway, which is manifested more strongly in certain oncology indication. The concept, I think, is quite easy to understand, but we actually do not have anyone trying this so far, as far as we know, in the clinical space. We probably are, it is still the first company pushing this ATTC composition into clinical trial globally first in the upcoming month. The other thing that is also quite new is this particular small molecule drug, we call PI3KPIKK. It is basically focused on a pathway called PAM, PAM pathway. There are no commercial drugs on, you know, the PAM pathway yet. The reason is that it is a very toxic molecule. I think the scientific community is already quite well aware and has a good consensus that this particular molecule targeting this pathway is very effective in eliminating tumors. Unfortunately, it is just too toxic. I think this is a very important point, right? For our ATTC, we are not just limiting to this HER2 with PI3K combination. We are going to have different combinations. A lot of investors ask us, what other are we thinking about? Think along the line of small molecule drug, which may be known to the scientific community, but was just too toxic. It was not able to be easily commercialized as a drug or approved as a drug. When this small molecule is loaded onto this ATTC platform, it becomes very selective. It becomes very destined for the tumor tissues. Then this toxic small molecule or this very potent small molecule will be deliberately delivered just to the tumor tissues and take its effect on eliminating the tumor tissues. This is basically the concept, right? As I have said, we do have a couple other combinations that we are working for. We have not disclosed that yet. We kind of disclosed the code name. The second molecule is called A580. We anticipate entering clinical trial around the middle part of next year. The third one is A830. We target it towards the end of next year to enter the clinical trial. As we disclose more data coming out from this number two and number three, we will also disclose their actual composition, right? Again, think along the line, small molecule drugs that are very effective, but were just too toxic in the past to be turned into a drug for cancer patients. Now, with this platform, we can load it on our ATTC and it becomes really targeted to the tumor tissues. Of course, just a caveat here, we have done a lot of very good work in the preclinical stage and animal stage. We have not tried on humans yet, right? That is why as the human trial kicks off in December and when the data starts to roll in, 2026, it will be very exciting for us as well as our potential licensing partners down the road to look at really how safe this ATTC platform can be, right? Just to dig a little bit deeper into this market that we are looking at, in fact, this particular slide that we created just last week even surprised me. I think many of you are much more familiar with some targets like EGFR, like HER2, right? Or maybe even RAS. Very few people talk about this PAM pathway, and it turns out that it is present in 50% of the solid tumors globally, right? This is not a small number. Why do not we know about this or why are we not more familiar with this is because this pathway or molecules targeting this pathway is just too toxic. It works very well, but it is just too toxic, right? For some of the major cancers which have this PAM pathway order, we kind of outline it here. Again, because we use HER2 as our large molecule, we also present some of the prevalence of different HER2 expression in the breast cancer space. You know, the clinical trials that we plan to kick off at this stage, this is our plan. You may notice this is also slightly different from our tradition, the tradition of HUTCHMED by doing things one at a time, right? We want to go a little bit more aggressive this time. We are working on different tumors in different cohorts at the same time. You may notice that we are also working on the later line, like the second line, third line indication, as well as the first line indication, at the same time. As you may know, the competitive landscape has dramatically changed in China the last two, three years with a lot of these licensing deals providing a lot of funding and a lot of bullets for our competitors to work faster and go into innovative modality earlier and sooner. We need to also pick up our speed. We now have a much stronger balance sheet of about $1.4 billion cash, and we want to put this cash into the right use by working on multiple trials. If you look at this, we also have a cohort looking at HER2 low, which is also a very sizable market out there. We have not disclosed the tumor. I am pretty sure we will disclose it in the near future. These are all very large addressable markets that we are working on. That is kind of our current plan for ATTC. This is another slide just to give you an idea of the prevalence of this PAM altered pathway in different types of cancers. Of course, we have the HER2 antibody or target preference in different types of tumors. Definitely watch out for one thing that we are trying to see whether it works for HER2 low. Not just HER2 positive, but also HER2 low, which again is another big market out there. Again, we have not disclosed what other antibody that we are working on. Someone may say like, why HER2, you know, why not something more, you know, even more crazy or even more innovative than that. I think at this stage, this PAM or this PI3K small molecule is new. It's not new to us, but it's new to the clinical space. We haven't put it into clinical trial yet. We want to kind of conserve the riskiness to that part. Whereas for the large molecule part, the antibody part, we are picking HER2 deliberately, which is a very good, well-established, very well-known profile antibody. Also for the linker, we kind of have not elaborated too much on, but this is also a very well-established linker that we are using. You know, the most innovative part, or the part that the clinical space hasn't seen too much data is actually the small molecule part, the small molecule payload. The upcoming few months, we are going to see two things. Number one, whether this small molecule drug does work well for cancer. Number two, whether putting this large molecule linker and a small molecule together, whether this construct conceptually is stable enough when injected into a human body and whether this will have good efficacy and more importantly, safety. One last point I want to emphasize about ATTC is that we call it a chemo free conjugate. Again, this is in contrast to the ADC out in the market or under development, which still rely on the chemotoxin, which is kind of like a non-specific toxin attacking all the tissues. With our chemo free ATTC molecule, many people are asking us, are we going to replace chemotherapy or are we going to replace ADC? I think the path, at least at this juncture, the path that we want to take is not necessarily to replace, but to be potentially used in combination, in combination with chemotherapy, of course, preferably in the early line setting, and also in combination with ADC out there. We've got very good animal data showing that it does work very well. Now is to put the test into human trial. I noticed that I have roughly five minutes left, so I'll just pick one slide and I will just go into some of the questions that are already on the line. This is kind of our roadmap, still mostly focusing on our existing pipeline, not too many ATTC molecules out there, right? It's still a very busy, very eventful next two years, even from our old pipeline. I would have to say that if this ATTC platform starts to deliver the value or the impact from this ATTC platform, maybe even bigger than what you see on this particular slide coming out from our established late stage pipeline. I will wrap up here and I will go into a couple of questions here. First question, let's see. Can you elaborate on China growth driver versus US EU market? I think China continues to present one of the largest patient populations, but then the pricing is a little bit compressed, right? Whereas the US and EU market definitely have better pricing for our drugs. You know, we will continue to do both, right? China is our home base. We develop many innovative drugs from our excellent scientists from China, but we will definitely try to bring this drug to all around the world, definitely include US and EU market. The next question is, you know, can you discuss the clinical timeline and upcoming milestones for ATTC program? Yes. The three that we have disclosed, we expect to kickstart the first one December into human trial, and then the second one around the middle part of next year, and then the third one towards the end of next year. Hopefully by the end of next year, we will have three ATTC molecules in clinical trial. Next question is, how is HUTCHMED leveraging strategic partnership to a very, very good question. I think we do have a very strong balance sheet, right? We think that, you know, with our many molecules coming out from the ATTC platform, we are definitely very open to outlying some of that, even in the early stage development, right? Because it not just validate, and we're definitely looking for a multinational pharma to be a potential partner, right? Because it not just going to help validate the science, but it also going to bring in potential upfront payment, which will again help us to be very self-sufficient to support even a bigger pipeline coming out from the ATTC program down the road. The next and last question, a little bit similar, how do, how will we allocate the capital and commercialization of our oncology drugs? For the overseas market, we will look for multinational partners. We've enjoyed a very good partnership with AstraZeneca, with Takeda. For China, we plan to use our own sales team to do the commercialization. We have about 700 people. They're very well trained. They're definitely ready for more products to commercialize in China and to support our home base. With that, I think I have about 30 seconds left, and I want to thank everyone who has been listening to our presentation and everyone who has been supportive on HUTCHMED and definitely looking forward to an even more exciting 2026. Thank you everyone.